Terri L. Parker

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer”.

Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer

JCI Insight(2020)10.1172/jci.insight.129353

N/A

2.2DataRank · unranked

62 citations

Federica Costa, Rituparna Das, Alyssa Duffy, Mehmet Samur, Samuel S. McCachren +17 more

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.18_suppl.lba3

N/A

0DataRank · unranked

31 citations

Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina A. Singh +15 more

Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies

Clinical Lymphoma Myeloma & Leukemia(2021)10.1016/j.clml.2021.01.003

N/A

0DataRank · unranked

1 citations

Jan Philipp Bewersdorf, David M. Swoboda, Wei Wei, Lohith Gowda, Thomas Prébet +10 more